The firm issued an outperform rating and a $28.00 price target on the biotechnology company’s stock. See Trillium Therapeutics Inc. (TRIL) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. james@trilliumtherapeutics.com. Create a list of the investments you want to track. Evercore ISI started coverage on shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) in a research report report published on Monday, Benzinga reports. 141 institutions hold shares in Trillium Therapeutics Inc. (TRIL), with institutional investors hold 68.87% of the company’s shares. Trillium Therapeutics Inc TRIL ... are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst … There are currently no items in this Watchlist. The shares outstanding are 100.71M, and float is at 83.86M with Short Float at 10.62%. Tel: +1 416.595.0627, James Parsons The company’s shares closed last Monday at $3.92. Cambridge, MA 02140 TRIL.CA updated stock price target summary. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an IgG4 Fc region instead of an IgG1 Fc. Analyst Coverage Trillium is followed by the analysts listed above. Cookie Notice (). Shares of NASDAQ:TRIL opened at $6.78 on Tuesday. Log in to see them here or sign up to get started. 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 Evercore ISI initiates coverage on Trillium Therapeutics (NASDAQ: TRIL) with a Outperform rating. Subscriber Agreement & Terms of Use, Find the latest Trillium Therapeutics Inc. (TRIL) stock quote, history, news and other vital information to help you with your stock trading and investing. The company’s shares closed last Monday at $3.92. Cowen & Co. analyst Boris Peaker maintained a Buy rating on Trillium Therapeutics (TRIL – Research Report) today. How is Trillium Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts? Institutions hold 68.87% of the Float. The shares outstanding are 100.71M, and float is at 83.86M with Short Float at 10.62%. 47.7%. Find the latest analyst research for Trillium Therapeutics Inc. Common Shares (TRIL) at Nasdaq.com. 141 institutions hold shares in Trillium Therapeutics Inc. (TRIL), with institutional investors hold 68.87% of the company’s shares. Chief Financial Officer The stock has a consensus analyst rating of "Buy." Summary. Cowen & Co. analyst Boris Peaker maintained a Buy rating on Trillium Therapeutics today. Trillium Therapeutics Inc. (TRIL) shares are trading at lower $14.97 and the avg recommendation for the stock is Strong Buy, while the current analyst price target stands at $11.02. Mississauga, ON L5L 1J9 TTI-621 is a potent dual function molecule that is designed to inhibit CD47 on the tumor cell and simultaneously deliver a strong activating signal to the immune system, whereas most competitor CD47 blockers require a second drug for full activation. Tel: +1 416.595.0627 x232 Trillium Therapeutics has a 1-year low of $0.24 and a 1-year high of $7.97. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Finally, Evercore ISI assumed coverage on shares of Trillium Therapeutics in a research note on Monday, October 12th. Trillium Therapeutics Inc. analyst estimates, including TRIL earnings per share estimates and analyst recommendations. Trillium does not, by its reference above, imply its endorsement of or concurrence with such information, conclusions or recommendations. Historical and current end-of-day data provided by FACTSET. Several brokerages recently commented on TRIL. The company’s shares closed last Monday at $5.22. Trillium Therapeutics is an immuno-oncology company developing innovative therapies for the treatment of cancer. We employ biologic and small molecule-based approaches that enhance the ability of the patient’s own immune system … Amount of Analyst Coverage Trillium Therapeutics has received no research coverage in the past 90 days. 5 Wall Street analysts have issued ratings and price targets for Trillium Therapeutics in the last 12 months. 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 Their average twelve-month price target is $21.25, predicting that the stock has a possible upside of 76.64%. 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 100 Cambridgepark Drive, Suite 510 Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies … Some of the cookies we use are essential for parts of the website to operate and cannot be switched off in our systems. USA To add more color to this target, the company’s high over the last year is $16.89 and the low is $0.24. Cambridge Office. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $21.25. Cambridge Office. Cambridge Office. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Privacy Notice, and Bloom Burton cut Trillium Therapeutics from a "buy" rating to an "accumulate" rating … Visit a quote page and your recently viewed tickers will be displayed here. Please note that any opinions, estimates or forecasts regarding Trillium's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Trillium or its management. By using this site you agree to the According to TipRanks.com, Peaker is a 2-star analyst with an average return of -0.2% Something went wrong while loading Watchlist. A "buy" rating indicates that analysts believe TRIL will outperform the market and that investors should add to their positions of Trillium Therapeutics. TTI-622 is Trillium’s second SIRPαFc fusion protein. Canada ... Future Dividend Coverage: ... Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of … Tel: +1 857.412.7029, 2488 Dunwin Drive A number of other equities research analysts have also recently commented on the stock. Trillium Therapeutics presently has a consensus rating of Buy and a consensus price target of $7.13. Institutions hold 68.87% of the Float. Trillium Therapeutics is a clinical stage immuno-oncology company based in Cambridge, MA and Toronto, ON. Intraday Data provided by FACTSET and subject to terms of use. They set an “outperform” rating and a $28.00 price target on the stock. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Trillium Therapeutics (TRIL +2.3%) opens higher after Evercore ISI launches coverage at Outperform with a Street-high $28 price target, and a $60 bull case if Trillium … Forecasted annual earnings growth. According to TipRanks.com , Peaker is a 4-star analyst with an average return of 4.4% and a 41.6% success rate. Evercore uses cookies to give you the best experience on our website. Please note that any opinions, estimates or forecasts regarding Trillium's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Trillium … For the best MarketWatch.com experience, please update to a modern browser. Trillium Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a market capitalization of $477.08 million, a price-to-earnings ratio of -3.37 and a beta of 2.05. This browser is no longer supported at MarketWatch. Olo, maker of restaurant-ordering tech, shares pop 28% in IPO, Dow trades fractionally higher, but Nasdaq slides ahead of Fed decision, Amazon jumps into health care, will provide telemedicine service to employers nationwide, Amid vaccine hurdles, EU battles to save summer vacations with COVID travel pass, Auto Parts Stocks Can Shift Higher, Analyst Says, Bond king Bill Gross says he made $10 million shorting GameStop, WHO urges countries to keep using AstraZeneca vaccine as ‘benefits outweigh risks’, COVID-19 vaccines get an endorsement from Trump, as daily U.S. deaths rise back above 1,000, Eviction filings increased after CDC issued nationwide moratorium, government report shows, TRIL will report 2020 earnings on 03/08/2022, TRIL will report Q4 2020 earnings on 05/07/2021.
Ged Kearney Cooper, Overwatch Poster Uk, Cj Stander Farm, Wesley Crusher First Time On Bridge, Bedankt Voor De Snelle Terugkoppeling, Wicket Cricket Manager Unlimited Money, Who Owns Farm Boy,